Jane Street’s Annovis Bio ANVS Stock Holding History

Jane Street’s Portfolio ANVS Stock Details ANVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$81.8K	Sell	36,700 -42,500	-54%	-$117K	﹤0.01%	10736
2025 Q4	$274K	Buy	+79,200	New	+$238K	﹤0.01%	9043

Other funds holding ANVS

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

MFG

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

Jane Street's ANVS Position: Q1 2026 in Review

Jane Street sold out of Annovis Bio (ANVS) in Q1 2026, closing a stake of 251,157 shares — an estimated $689K sold.

Jane Street first reported a position in ANVS in Q1 2023 and held it in 7 quarters. The position peaked at $869K in Q4 2025. 56 funds tracked by Wall St. Rank hold ANVS as of Q1 2026.

Jane Street reported no remaining Annovis Bio position as of Q1 2026 after selling out during the quarter.
Jane Street sold 251,157 Annovis Bio shares in Q1 2026, an estimated $689K.
Jane Street first reported a position in Annovis Bio in Q1 2023 and held it in 7 quarters.
Jane Street's Annovis Bio position peaked at $869K in Q4 2025.
56 funds tracked by Wall St. Rank held Annovis Bio as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.